Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 20 - Number 10
Review Article
The Roles of Alternative Splicing in Tumor-immune Cell Interactions
, 20(10): 729 - 740Yue Wang, Honglei Zhang*, Baowei Jiao*, Jianyun Nie*, Xiyin Li, Wenhuan Wang and Hairui Wang
DOI: 10.2174/1568009620666200619123725
Review Article
Tumor-Induced Metabolism and T Cells Located in Tumor Environment
, 20(10): 741 - 756Sara Iranparast, Sanaz Tayebi, Fatemeh Ahmadpour and Bahman Yousefi*
DOI: 10.2174/1568009620666200720010647
Review Article
Regulation of Breast Cancer Progression by Noncoding RNAs
, 20(10): 757 - 767Ravishkumar L. Akshaya, Muthukumar Rohini and Nagarajan Selvamurugan*
DOI: 10.2174/1568009620666200712144103
Review Article
Targeting NUPR1 for Cancer Treatment: A Risky Endeavor
, 20(10): 768 - 778Salma M.A. Mansour, Sahar A. Ali, Shaira Nofal and Sameh H. Soror*
DOI: 10.2174/1568009620666200703152523
Review Article
Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
, 20(10): 779 - 788Wujun Zou*, Xiaoyan Hu and Liang Jiang*
DOI: 10.2174/1568009620999200730183631
Review Article
Systematic Review Article
Prognostic Value of MiRNAs in Patients with Laryngeal Cancer: A Systematic Review and Meta-Analysis
, 20(10): 802 - 810Wujun Zou, Xiaoyan Hu, Dingting Wang and Liang Jiang*
DOI: 10.2174/1568009620666200806094709
Clinical Trial
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
, 20(10): 811 - 817Sven Nilsson, Alexander Stein, Christian Rolfo, Anne L. Kranich, Julia Mann, Konstantinos Papadimitriou, Susann Theile, Stefanie Amberg and Carsten Bokemeyer*
DOI: 10.2174/1568009620666200628105727
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Webmaster Contact: info@benthamscience.net